The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2021 | Updates to look out for at ESMO WCGIC 2021
Lei Deng, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares exciting updates being presented at the ESMO World Congress on Gastrointestinal Cancer 2021, which includes data suggesting a link between inflammatory markers and enhanced response from immune checkpoint inhibitors. There is currently no consensus on which biomarkers should be used, especially in the field of gastric and esophageal cancers, with biomarkers such as obesity not yielding consistent results. Utilizing predictive biomarkers to identify patients who will benefit from receiving immune checkpoint inhibitors will improve patient outcomes. This interview took place at the ESMO World Congress on Gastrointestinal Cancer 2021.
